Advertisement

Index by author

July 01, 1995; Volume 23,Issue 7

A

  1. Acheampong, A A

    1. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
      A A Acheampong, M Shackleton and D D Tang-Liu
      Drug Metabolism and Disposition July 1995, 23 (7) 708-712;

  2. Agen, C

    1. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;

B

  1. Balani, S K

    1. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

  2. Bocci, G

    1. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;

  3. Born, S L

    1. Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis.
      S L Born, G H John, G R Harlow and J R Halpert
      Drug Metabolism and Disposition July 1995, 23 (7) 702-707;

  4. Bowers, G D

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

  5. Bracken, W

    1. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

  6. Bullock, P

    1. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

  7. Buters, J T

    1. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;

C

  1. Cannell, R J

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

  2. Carlson, T J

    1. Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

  3. Carrel, B K

    1. Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

  4. Castagnoli, N

    1. Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

  5. Chen, I W

    1. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
      J H Lin, I W Chen, K J Vastag and D Ostovic
      Drug Metabolism and Disposition July 1995, 23 (7) 730-735;

  6. Cribb, A

    1. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6.
      A Cribb, C Nuss and R Wang
      Drug Metabolism and Disposition July 1995, 23 (7) 671-675;

D

  1. Danesi, R

    1. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;

  2. Dawson, M J

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

  3. Del Tacca, M

    1. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;

  4. Di Paolo, A

    1. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;

  5. Draper, A

    1. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

  6. Dwyer, L M

    1. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

E

  1. Eddershaw, P J

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

  2. Elder, C A

    1. Interspecies scaling of a thienodiazepine platelet-activating factor receptor antagonist.
      C A Elder and M W Modi
      Drug Metabolism and Disposition July 1995, 23 (7) 776-778;

  3. Ellis, J D

    1. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

  4. Estabrook, R W

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

F

  1. Ferrero, J L

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

G

  1. Gonzalez, F J

    1. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;

H

  1. Halpert, J R

    1. Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis.
      S L Born, G H John, G R Harlow and J R Halpert
      Drug Metabolism and Disposition July 1995, 23 (7) 702-707;

  2. Hardwick, J P

    1. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;

  3. Harlow, G R

    1. Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis.
      S L Born, G H John, G R Harlow and J R Halpert
      Drug Metabolism and Disposition July 1995, 23 (7) 702-707;

  4. Ho, J

    1. Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

I

  1. Iga, T

    1. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;

  2. Innocenti, F

    1. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;

  3. Iyer, K R

    1. Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

J

  1. John, G H

    1. Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis.
      S L Born, G H John, G R Harlow and J R Halpert
      Drug Metabolism and Disposition July 1995, 23 (7) 702-707;

  2. Jones, J P

    1. Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

K

  1. Katashima, M

    1. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;

  2. Kauffman, L R

    1. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

  3. Knaggs, A R

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

  4. Kocarek, T A

    1. Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.
      R C Zangar, K J Woodcroft, T A Kocarek and R F Novak
      Drug Metabolism and Disposition July 1995, 23 (7) 681-687;

  5. Korzekwa, K R

    1. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;

  6. Kukulka, M J

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

  7. Kuo, B S

    1. Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

L

  1. Lee, R D

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

  2. Lin, J H

    1. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
      J H Lin, I W Chen, K J Vastag and D Ostovic
      Drug Metabolism and Disposition July 1995, 23 (7) 730-735;

M

  1. Malspeis, L

    1. Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
      L R Phillips, L Malspeis and J G Supko
      Drug Metabolism and Disposition July 1995, 23 (7) 676-680;

  2. Manchee, G R

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

  3. Mathews, B S

    1. Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

  4. Modi, M W

    1. Interspecies scaling of a thienodiazepine platelet-activating factor receptor antagonist.
      C A Elder and M W Modi
      Drug Metabolism and Disposition July 1995, 23 (7) 776-778;

  5. Mulford, D J

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

N

  1. Nardini, D

    1. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
      F Innocenti, R Danesi, A Di Paolo, C Agen, D Nardini, G Bocci and M Del Tacca
      Drug Metabolism and Disposition July 1995, 23 (7) 713-717;

  2. Novak, R F

    1. Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.
      R C Zangar, K J Woodcroft, T A Kocarek and R F Novak
      Drug Metabolism and Disposition July 1995, 23 (7) 681-687;

  3. Nuss, C

    1. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6.
      A Cribb, C Nuss and R Wang
      Drug Metabolism and Disposition July 1995, 23 (7) 671-675;

O

  1. Ostovic, D

    1. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
      J H Lin, I W Chen, K J Vastag and D Ostovic
      Drug Metabolism and Disposition July 1995, 23 (7) 730-735;

P

  1. Parkinson, A

    1. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

  2. Pearce, R

    1. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

  3. Peterson, L

    1. Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

  4. Phillips, L R

    1. Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
      L R Phillips, L Malspeis and J G Supko
      Drug Metabolism and Disposition July 1995, 23 (7) 676-680;

  5. Pitzenberger, S M

    1. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

  6. Podval, J

    1. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

  7. Prueksaritanont, T

    1. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

R

  1. Rodrigues, A D

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

  2. Rose, J Q

    1. Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

S

  1. Sawada, Y

    1. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;

  2. Shackleton, M

    1. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
      A A Acheampong, M Shackleton and D D Tang-Liu
      Drug Metabolism and Disposition July 1995, 23 (7) 708-712;

  3. Shet, M S

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

  4. Shou, M

    1. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
      J T Buters, M Shou, J P Hardwick, K R Korzekwa and F J Gonzalez
      Drug Metabolism and Disposition July 1995, 23 (7) 696-701;

  5. Sidebottom, P J

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

  6. Stuhler, J D

    1. Disposition and cardioselectivity of MDL 74,405, a vitamin E-like free radical scavenger, in rats and dogs after intravenous infusion.
      B S Kuo, B S Mathews, J D Stuhler, B K Carrel, J Ho and J Q Rose
      Drug Metabolism and Disposition July 1995, 23 (7) 757-764;

  7. Sugiura, M

    1. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;

  8. Supko, J G

    1. Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog.
      L R Phillips, L Malspeis and J G Supko
      Drug Metabolism and Disposition July 1995, 23 (7) 676-680;

  9. Surber, B W

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

  10. Sutherland, D R

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

T

  1. Tang-Liu, D D

    1. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
      A A Acheampong, M Shackleton and D D Tang-Liu
      Drug Metabolism and Disposition July 1995, 23 (7) 708-712;

  2. Theoharides, A D

    1. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

  3. Thomas, P

    1. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

  4. Thomas, S B

    1. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
      A D Rodrigues, D J Mulford, R D Lee, B W Surber, M J Kukulka, J L Ferrero, S B Thomas, M S Shet and R W Estabrook
      Drug Metabolism and Disposition July 1995, 23 (7) 765-775;

  5. Trager, W F

    1. Stereoselectivity and isotope effects associated with cytochrome P450-catalyzed oxidation of (S)-nicotine. The possibility of initial hydrogen atom abstraction in the formation of the delta 1', 5-nicotinium ion.
      T J Carlson, J P Jones, L Peterson, N Castagnoli, K R Iyer and W F Trager
      Drug Metabolism and Disposition July 1995, 23 (7) 749-756;

V

  1. Varga, S L

    1. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
      T Prueksaritanont, S K Balani, L M Dwyer, J D Ellis, L R Kauffman, S L Varga, S M Pitzenberger and A D Theoharides
      Drug Metabolism and Disposition July 1995, 23 (7) 688-695;

  2. Vastag, K J

    1. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
      J H Lin, I W Chen, K J Vastag and D Ostovic
      Drug Metabolism and Disposition July 1995, 23 (7) 730-735;

  3. Veltman, J

    1. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
      P Bullock, R Pearce, A Draper, J Podval, W Bracken, J Veltman, P Thomas and A Parkinson
      Drug Metabolism and Disposition July 1995, 23 (7) 736-748;

W

  1. Wang, R

    1. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6.
      A Cribb, C Nuss and R Wang
      Drug Metabolism and Disposition July 1995, 23 (7) 671-675;

  2. Waterhouse, I

    1. Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite.
      R J Cannell, A R Knaggs, M J Dawson, G R Manchee, P J Eddershaw, I Waterhouse, D R Sutherland, G D Bowers and P J Sidebottom
      Drug Metabolism and Disposition July 1995, 23 (7) 724-729;

  3. Woodcroft, K J

    1. Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.
      R C Zangar, K J Woodcroft, T A Kocarek and R F Novak
      Drug Metabolism and Disposition July 1995, 23 (7) 681-687;

Y

  1. Yamamoto, K

    1. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
      M Katashima, K Yamamoto, M Sugiura, Y Sawada and T Iga
      Drug Metabolism and Disposition July 1995, 23 (7) 718-723;

Z

  1. Zangar, R C

    1. Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes.
      R C Zangar, K J Woodcroft, T A Kocarek and R F Novak
      Drug Metabolism and Disposition July 1995, 23 (7) 681-687;
Back to top

In this issue

Advertisement